ATRIAL FIBRILLATION ONSET RISK IN PATIENTS WITH METABOLIC SYNDROME: PROSPECTIVE STUDY
https://doi.org/10.15829/1560-4071-2014-12-25-30
Abstract
Aim. To evaluate the usefulness of atrial fibrillation (AF) risk predictors for assessment for long-term and short-term risk of its development in patients with metabolic syndrome (MS) during prospective study.
Material and methods. During 1998-2008 y. we studied 1968 patients with MS at the age of 45-75 y. o. All patients underwent common clinical investigation, hemodynamics assessment, late atrial potentials (LAP), P-wave dispersions (Pd), transesophageal electrocardiostimulation with AF risk index (AFRI). After inclusion into the study the patients were followed-up during 1-5 years. The endpoint was absence or presence of AF.
Results. In 176 (8,94%) of the patients studied during 4-4,5 year prospective study we marked the onset of paroxysmal and persistent types of AF. If during single assessment of the patients with MS older than 55 y. o. and BMI ≥30 kg/sq.m there is atrial dilatation and/or LAP, pathological values of Pd, and induction of AF with electrocardiostimulation which presuppose long-term risk of AF. Short-term risk (during 1-2 years after the first year postobservational) of AF development in MS can be evaluated only in dynamics: while lowering of AFRI by 20% and more every 3-4 months of observation leads to development of AF during 1-2 years in MS, and in AFRI less than 3 Units with further decline of this parameter by 90% and more during 1-3 months — during 6 months after investigation.
Conclusion. Complex investigation of MS patients, that includes assesssment of LAP, Pd, AFRI, improves the evaluation of longand short-term risks of AF development.
About the Authors
A. I. Olesin
North-Western State Medical University n. a. I. I. Mechnikov, Saint-Petersburg
Russian Federation
Russian Federation
V. A. Litvinenko
St. Elisabeth City Hospital, Saint-Petersburg
Russian Federation
Russian Federation
A. V. Al-Barbari
St. Elisabeth City Hospital, Saint-Petersburg
Russian Federation
Russian Federation
I. V. Konstantinova
North-Western State Medical University n. a. I. I. Mechnikov, Saint-Petersburg
Russian Federation
Russian Federation
Z. Yu. Smolin
St. Elisabeth City Hospital, Saint-Petersburg
Russian Federation
Russian Federation
O. N. Prosyanikova
St. Elisabeth City Hospital, Saint-Petersburg
Russian Federation
Russian Federation
References
1. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. Europace. 2012; 14(10): 1385-413.
2. Diagnostics and treatment of atrial fibrillation. National clinical guidelines 5 ed. Moscow: 2012. Russian (Диагностика и лечение фибрилляции предсердий. Национальные клинические рекомендации 5-е издание. М.: 2012).
3. Braunwald’s Heart Disease. A textbook of cardiovascular medicine. 9th ed. Libby P. et al., Phyladelfhia, W. B. Saunders Company; 2011.
4. Clinical arrhythmology. Ed. by Ardashev AV. Medpractica-M.; 2009. Russian (Клиническая аритмология. Под ред. Ардашева А. В. Медпрактика-М.; 2009).
5. Galito L, Badano L, Fox K, et al. The European Association of Echocardiography (EAE) Textbook of Echocardiography. Oxford Academ.; 2011.
6. Ivanov GG, Gracheva SV, Syrkina AL. Signal-averaged electrocardiography. Moscow.: “Triada-X”; 2003. Russian. (Иванов Г. Г., Грачева С. В., Сыркина А. Л. Электрокардиогр афия высокого разрешения. Москва.: “Триада-Х”; 2003).
7. Olesin AI, Shabrov AV, Sheglova EA, et al. Assessment of use of various cardiac pacing modes for selection of antiarrhythmic therapy for prevention of recurrent attacks of atrial fibrillation and flutter. Kadiologiya 2002; 4: 47-50. Russian. (Олесин А. И., Шабров А. В., Щеглова Е. А. и др. Использование различных режимов кардиостимуляции для выбора противорецидивной терапии пароксизмов мерцания и трепетания предсердий у больных ишемической болезнью. Кардиология 2002; 4: 47-50).
8. Olesin AI, Prosynikova ON. Method for determine risk development of atrial fibrillation. Patent RU № 2497446, 2013. Russian (Олесин А. И., Просяникова О. Н. Способ определения риска развития фибрилляции предсердий — Патент Российской Федерации № 2497446, опубликован 10.11.2013 г., Бюллетень изобретений № 31).
9. Perez MV, Dewey FE, Marcus R, et al. Electrocardiographic predictors of atrial fibrillation. Am Heart J. 2009; 158(4): 622-8.
10. Schnabel RB, Sullivan LM, Levy D, et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet. 2009; 373: 739-45.
11. Ivanov AP, Elgart IA, Gornostaeva TS, et al. To determine the diagnostic value of transient atrial fibrillation originated by transesophageal pacing in patients with stable angina. Vest. Arhythmol. 2005; 35(5): 35-9. (Иванов А. П., Эльгардт И. А., Горностаева Т. С. и др. Диагностическое значение фибрилляции предсердий, индуцированной при чреспищеводной электрокардиостимуляции у больных стабильной стенокардией. Вестник аритмологии, 2005; 38(5): 35-9).
12. Watanabe H, Tanabe N, Watanabe T, et al. Metabolic Syndrome and Risk of Development of Atrial Fibrillation. The Niigata Preventive Medicine Study. Circulation 2008; 117(5): I255-60.
Review
For citations:
Olesin A.I., Litvinenko V.A., Al-Barbari A.V., Konstantinova I.V., Smolin Z.Yu., Prosyanikova O.N. ATRIAL FIBRILLATION ONSET RISK IN PATIENTS WITH METABOLIC SYNDROME: PROSPECTIVE STUDY. Russian Journal of Cardiology. 2014;(12):25-30. (In Russ.) https://doi.org/10.15829/1560-4071-2014-12-25-30
Views:
821
Email this article 